COVID-19 Resource Center
COVID-19 Resource Center
Source/Disclosures
Source:

Press Release

Disclosures: Beyer is an employee of Ascend.
June 19, 2020
1 min read
Save

Ascend, Stanford to study SARS-CoV-2 exposure in patients on dialysis

Source/Disclosures
Source:

Press Release

Disclosures: Beyer is an employee of Ascend.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Starting in July, researchers from Stanford University School of Medicine will collaborate with dialysis testing laboratory Ascend to examine the prevalence of SARS-CoV-2 antibodies in patients on dialysis, according to a press release.

“The high-risk dialysis patient population needs to interact with the health care system to receive life-sustaining therapy,” Paul F. Beyer, CEO of Ascend, told Healio Nephrology. “During a worldwide pandemic, this makes them especially vulnerable. Understanding their exposure to SARS-CoV-2 will be extremely valuable.”

doctor with chart
Source: Adobe Stock

Of the millions of samples Ascend processes each month, Beyer said the researchers will select a subsample of approximately 30,000 to 40,000 patients who are representative of the dialysis population in the United States, with consideration of age, gender, race/ethnicity and region.

Utilizing the SARS-CoV-2 Total Antibody assay (Siemens Healthineers), researchers will follow antibody responses for 12 months with estimations made as to the seroprevalence of SARS-CoV-2 antibodies. Beyer added that differences in seroconversion by age, sex, race/ethnicity and geographic regions will be explored.

“By following seroprevalence status over time, the study will estimate the potential need for health care capacity planning and vaccine requirements as the COVID-19 pandemic continues,” Beyer said.